{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:23:06Z","timestamp":1792714986038,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011948","name":"Abbott Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ahj.2026.107367","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:10:40Z","timestamp":1770016240000},"page":"107367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Left Atrial Appendage Occlusion Versus NOACs in patients With Atrial Fibrillation: Rationale and Design of the CATALYST Trial"],"prefix":"10.1016","volume":"296","author":[{"given":"Vivek Y.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan John","family":"Camm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiko","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanunjaya","family":"Lakkireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107367_bib0001","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla","year":"2013","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.ahj.2026.107367_bib0002","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1016\/j.ahj.2026.107367_bib0003","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century","volume":"167","author":"Ball","year":"2013","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.ahj.2026.107367_bib0004","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2026.107367_bib0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillation Study. Final results","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107367_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beha.2013.07.009","article-title":"Disadvantages of VKA and requirements for novel anticoagulants","volume":"26","author":"Shameem","year":"2013","journal-title":"Best Practice & Research Clinical Haematology"},{"key":"10.1016\/j.ahj.2026.107367_bib0007","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.ahj.2026.107367_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation","volume":"83","author":"Joglar","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.ahj.2026.107367_bib0009","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"European Heart Journal"},{"key":"10.1016\/j.ahj.2026.107367_bib0010","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.ahj.2026.107367_bib0011","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40266-017-0477-3","article-title":"Underuse of Oral Anticoagulants and Inappropriate Prescription of Antiplatelet Therapy in Older Inpatients with Atrial Fibrillation","volume":"34","author":"Averlant","year":"2017","journal-title":"Drugs & Aging"},{"key":"10.1016\/j.ahj.2026.107367_bib0012","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","article-title":"Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation","volume":"69","author":"Marzec","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.ahj.2026.107367_bib0013","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"The Annals of Thoracic Surgery"},{"key":"10.1016\/j.ahj.2026.107367_bib0014","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.4244\/EIJ-D-19-00128","article-title":"Prevalence of extra-appendage thrombosis in non-valvular atrial fibrillation and atrial flutter in patients undergoing cardioversion: a large transoesophageal echo study","volume":"5","author":"Cresti","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2026.107367_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2021.10.023","article-title":"4-year outcomes after left atrial apendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation","volume":"79","author":"Osmancik","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.ahj.2026.107367_bib0016","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/eurheartj\/ehx037","article-title":"Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative","volume":"39","author":"Lansky","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1016\/j.ahj.2026.107367_bib0017","first-page":"4","article-title":"Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies","volume":"19","author":"Tzikas","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2026.107367_bib0018","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"10.1016\/j.ahj.2026.107367_bib0019","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2026.107367_bib0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2026.107367_bib0021","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2026.107367_bib0022","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2026.107367_bib0023","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1253\/circj.CJ-11-1140","article-title":"Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation","volume":"76","author":"Yamashita","year":"2012","journal-title":"Circulation Journal"},{"key":"10.1016\/j.ahj.2026.107367_bib0024","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.ahj.2026.107367_bib0025","first-page":"1925","article-title":"Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: A pooled, patient-level analysis of the WATCHMAN randomized trial experience","volume":"8","author":"Price","year":"2015","journal-title":"JACC: Cardiovascular Interventions"},{"key":"10.1016\/j.ahj.2026.107367_bib0026","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A graphical approach to sequentially rejective multiple test procedures","volume":"28","author":"Bretz","year":"2009","journal-title":"Statistics in Medicine"},{"key":"10.1016\/j.ahj.2026.107367_bib0027","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of the confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.ahj.2026.107367_bib0028","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.ahj.2026.107367_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure Device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.ahj.2026.107367_bib0030","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE): A randomized, controlled trial","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.ahj.2026.107367_bib0031","article-title":"5-year results from the AMPLATZER amuelt left atrial appendage occluder ranodmized controlled trial","volume":"S0735\u20131097","author":"Lakkireddy","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.ahj.2026.107367_bib0032","series-title":"Left atrial appendage closure after ablation for atrial fibrillation","author":"Wazni","year":"2014"},{"key":"10.1016\/j.ahj.2026.107367_bib0033","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2023.05.022","article-title":"Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation","volume":"264","author":"Kar","year":"2023","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.ahj.2026.107367_bib0034","article-title":"Catheter-based left atrial appendage CLOSURE in patients with atrial fibrillation at high risk of stroke and bleeding as compared to best medical therapy: Rationale and design of the prospective randomized CLOSURE-AF trial","volume":"292","author":"Landmesser","year":"2026","journal-title":"Journal of the American Heart Association"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:09:30Z","timestamp":1779091770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"alternative-id":["S0002870326000293"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107367","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Left Atrial Appendage Occlusion Versus NOACs in patients With Atrial Fibrillation: Rationale and Design of the CATALYST Trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107367"}}